About this trial
This project aims to evaluate the roles of the autonomic nervous system (ANS) and gut microbiota as correlates of clinical improvement in metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty liver disease (NAFLD) in response to a therapeutic regimen comprising resistance exercise and probiotic supplementation. The primary objective is to investigate the effects of these non-pharmacological interventions on MAFLD/NAFLD and to identify patient phenotypes based on baseline ANS profiles and gut microbiota composition that predict clinical responses.
Eligibility criteria
Qualifiers
Diagnosis of NAFLD/MAFLD or NASH (imaging or histological confirmation of fatty liver disease, e.g., ultrasound, MRI-PDFF, biopsy)
Age 18-60 years
Ability to understand the study procedures and provide informed consent.
Stable clinical condition for at least 3 months prior to study initiation.
Disqualifiers
Lack of fluency in English or Polish
Significant (structural) limitation of upper and/or lower limb mobility
Pregnancy or breastfeeding
Inability to understand instructions
Trial design
Treatments tested in this trial
- physical exercise programme
- probiotics supplementation
- Placebo
Treatment groups
Locations
Sponsors and collaborators
Nicolaus Copernicus University
Lead sponsor
University of Oxford
Collaborator
Medical University of Warsaw
Collaborator